Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways.

Independent Black Book user experience rankings spotlight vendors leading the modernization of health information management  from AI-powered coding to interoperable data systems.

Strong consumer demand and rapid market adoption drive CBDL's beverage expansion as top-selling CBD Lemonade, Raspberry Lemonade, and Lavender Lemonade hit the shelves of Smoking Scholars in New York City - setting the stage for record-breaking revenue in Q4 and beyond.

Acclaimed Facial Plastic Surgeon and Educator Joins CLn Skin Care

Enterprise Imaging and Cloud Solutions Drive Growth, Customer Satisfaction, and a Clinician-First Experience Across the U.S., Canada, and Government Health Systems

The recognition highlights Altior Healthcare's strong financial leadership and commitment to sustainable, patient-centered growth.

Honoring the dedicated professionals who ensure safe, effective, and compassionate care for our community

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST

mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial

~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~

Highlighting the Solutions Transforming Data Accuracy, Automation, and AI-Driven Revenue Integrity at the Minneapolis Convention Center, October 12–14, 2025

Delivering over two million hours of care while creating meaningful jobs for family caregivers.

Trusted U.S. wellness brand expands its line with ultra-pure DMSO liquids and roll-ons designed for versatility, transparency, and results.

Dr. Javad Sajan is the best female to male top surgeon

Serving 80% of the largest home care networks across North America, Sensi.AI is the new standard in senior care

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation.

New $10 mil building will help improve care by shortening wait times, improving diagnoses and letting patients and physicians build stronger bonds

PeekDirect™ Delivers Transparent and Affordable Pricing for Brand and Specialty Drugs to Reduce Prescription Costs for Employers and Patients

Belhaven's Investigational New Drug (IND) Application Receives FDA Authorization to Proceed

Established healthcare leader expands into sports nutrition sector with comprehensive performance-focused product line

- Clinical challenge: uncertainty in discharge and admission decisions for women at risk of preeclampsia

- PreFree: the first CE-marked, multimodal prediction model for preeclampsia (biomarkers + clinical data)

- Market launch in CE countries starting Q4 2025

The Naderi Center sees growing demand for revision rhinoplasty, with Dr. Shervin Naderi providing surgical and non-surgical solutions customized to patient needs, from advanced corrective surgery to filler-based nasal refinement.

Black Book Survey results reveal the twenty-five firms shaping the next generation of accountable care infrastructure  released in orchestration with the opening events of the National Association of Accountable Care Organizations (NAACOS) Fall 2025 Meeting in Washington, D.C.

The DEA Regulatory Revolving Door Spins Again

IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed

New research from Black Book benchmarks U.S. healthcare's ROI technology landscape - complimentary report now available to providers and payers.

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC study

These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor as a potential new option for people with moderately to severely active ulcerative colitis

Registrational Phase 3 study in ulcerative colitis and Phase 2b/3 study in Crohn's disease anticipated to begin patient enrollment in Q4 2025

Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models.

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION

The Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai"

Celebrating the vital role pharmacists play in patient health

Compassion Center Hosts its Coalition for Patient Rights' First-Ever Charity Hoedown - $1 Admission for a Full Day of Fun at the Paradise Recreation Center

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization.